Hengrui Pharma(SH:600276) Ge Long Hui·2025-09-03 08:09Core Viewpoint - Heng Rui Medicine has shown strong performance in the stock market, with significant price increases and new clinical trial approvals for innovative drugs [1] Group 1: Stock Performance - Heng Rui Medicine (600276.SH) saw a peak increase of 6.61% to 73.42 CNY, marking a new high since June 16, 2021, with a year-to-date increase of approximately 60% [1] - Heng Rui Medicine (1276.HK) rose by 8.14% to 87.05 HKD, approaching a historical closing high, with a trading volume of 1 billion HKD and a market capitalization of 577.8 billion HKD [1] - Since its listing on the Hong Kong Stock Exchange on May 23, the stock price has increased by 97.62% from the issue price of 44.05 HKD [1] Group 2: Drug Approvals - The company announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of SHR-A2009, an antibody-drug conjugate targeting HER3, which has no similar drugs approved globally [1] - Additionally, the company received approval for clinical trials of HRS-7172 tablets, a new type of small molecule inhibitor for cancer treatment, with no similar drugs approved domestically or internationally [1]